Europe
HOOKIPA Pharma Inc. announced that HOOKIPA’s management team will present and host one-on-one meetings at the following investor conferences in September
Motif Bio plc announces that its lender, Hercules Capital, Inc., has agreed to amend the Company’s loan and security agreement such that the next amortisation date is postponed from September 1 to October 1, 2019.
4TEEN4 Pharmaceuticals GmbH demonstrates that targeting the enzyme Dipeptidyl Peptidase 3 with its first-in-class therapeutic antibodyProcizumab normalises heart and kidney function ina preclinical models of acute heart failure with depressed contraction.
uniQure N.V. announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
Batavia Biosciences announced that the company has signed a license agreement to utilize Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines.
Akari Therapeutics, Plc announced that Clive Richardson, Chief Executive Officer, will participate and host investor meetings at the following September Conferences:
Strategic and operational leadership expanded for progressing broad pipeline
Horus Pharma announces the launch of a new 15ml bottle of Neovis Total Multi for the French, Belgian and Spanish markets.
Financing will support continued clinical development of gene therapies and surgical delivery systems for retinal diseases
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta isoform inhibitor, in patients with relapsed or refractory lymphoma.
PRESS RELEASES